We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 1

Figure 1. From: Metformin Extended Release Treatment of Adolescent Obesity.

Disposition of subjects. “Withdrew” refers to withdrawal of consent. One subject in the metformin hydrochloride extended release group withdrew consent at week 16 but returned for a measurement at week 100 (end of study). See text for further details.

. Arch Pediatr Adolesc Med. 2010 February;164(2):116-123.
2.
Figure 2

Figure 2. From: Metformin Extended Release Treatment of Adolescent Obesity.

Body mass index (BMI) (calculated as mean weight in kilograms divided by mean height in meters squared) (A) and adjusted change in BMI from baseline (B) (see text for further details). Data are plotted as the mean and 1 SE. Vertical dotted lines separate the study drug treatment (4–52 weeks) and post–study drug treatment (52–100 weeks) monitoring periods. Part A includes data for the run-in period (0–4 weeks). Metformin was given as metformin hydrochloride extended release.

. Arch Pediatr Adolesc Med. 2010 February;164(2):116-123.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk